AbbVie Inc (ABBV)vsAclarion Inc (ACON)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ACON
Aclarion Inc
$3.26
-3.26%
HEALTHCARE · Cap: $8.03M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 80760499% more annual revenue ($61.16B vs $75,730). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ACON
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for ACON.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Revenue surging 80.6% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ACON
The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 80.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ACON
The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while ACON is a hypergrowth play — different risk/reward profiles.
ACON carries more volatility with a beta of 1.14 — expect wider price swings.
ACON is growing revenue faster at 80.6% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 33/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Aclarion Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Aclarion Inc (ACON) is a leading healthcare technology company dedicated to enhancing patient care through non-invasive diagnostic solutions leveraging advanced data analytics and machine learning. The firm specializes in innovative imaging techniques that streamline treatment pathways for musculoskeletal conditions, equipping healthcare professionals with actionable insights to improve clinical outcomes while reducing costs. Positioned at the forefront of the digital health revolution, Aclarion is well-equipped to address the rising demand for effective diagnostic tools, significantly contributing to the evolution of healthcare delivery in a dynamic environment. With a strong focus on advancing patient management, Aclarion is set to redefine standards in the healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?